3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Osteoporosis
4
Prostatic Neoplasms
3
Breast Neoplasms
3
Vitamin D Deficiency
2
Polycystic Ovary Syndrome
2
Neoplasms
2
Cardiovascular Diseases
2
Vitamin D3
1
Neuroma
1
Melanoma, Cutaneous Malignant
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Locally Advanced Breast Cancer and Large Operable Breast Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Insulin Resistance
1
Fractures, Bone
1
Colorectal Adenocarcinoma
1
Interventions
Rituximab
23
Cyclophosphamide
11
Radiotherapy
8
Prednisone
8
Vincristine
7
Doxorubicin
7
Lenalidomide
6
Bendamustine Hydrochloride
5
Chlorambucil
4
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
obinutuzumab
2
liposomal amphotericin B
2
idelalisib
2
ibrutinib
2
fludarabine phosphate
2
VAP-cyclo protocol
2
Therapeutics
2
Psychiatric Rehabilitation
2
Levofloxacin
2
Interferon-alpha
2
Idarubicin
2
Epoetin Alfa
2
Early Intervention, Educational
2
Cyclosporine
2
Busulfan
2
zanubrutinib
1
tafasitamab
1
parsaclisib
1
orelabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell, Marginal Zone
×
Cholecalciferol
×
Clear all
NCT03078855
2024-09-04
ILyAD
University of Rochester
Phase 3
Completed
211 enrolled
13 charts